Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology. Aggarwal R, et al. Among authors: george d. Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31. Cancer. 2013. PMID: 23913744 Free PMC article. Clinical Trial.
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D. Powles T, et al. Among authors: george d. Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10. Br J Cancer. 2018. PMID: 30197417 Free PMC article. Clinical Trial.
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK, Zhu J, Gupta RT, McCall S, Jackson J, Kong EF, White JR, Cerqueira G, Gerding K, Simmons JK, George D, Zhang T. Labriola MK, et al. Among authors: george d. J Immunother Cancer. 2020 Mar;8(1):e000319. doi: 10.1136/jitc-2019-000319. J Immunother Cancer. 2020. PMID: 32221016 Free PMC article.
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD Jr, Pritchard JE, Leapman M, Gross CP, Dinan MA. Spees LP, et al. Among authors: george d. Cancer Med. 2021 Oct;10(19):6653-6665. doi: 10.1002/cam4.4201. Epub 2021 Sep 4. Cancer Med. 2021. PMID: 34480518 Free PMC article.
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).
Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D; Alliance for Clinical Trials in Oncology. Kim HL, et al. Among authors: george d. EBioMedicine. 2015 Sep 8;2(11):1814-20. doi: 10.1016/j.ebiom.2015.09.012. eCollection 2015 Nov. EBioMedicine. 2015. PMID: 26870806 Free PMC article.
1,777 results